Literature DB >> 12965943

Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens.

Luca Chiovato1, Francesco Latrofa, Lewis E Braverman, Furio Pacini, Marco Capezzone, Lucio Masserini, Lucia Grasso, Aldo Pinchera.   

Abstract

BACKGROUND: The development of antibodies to thyroid peroxidase, thyroglobulin, and thyroid-stimulating hormone (TSH) receptor is a main feature of autoimmune thyroid diseases.
OBJECTIVE: To investigate whether complete removal of thyroid antigens results in the abatement of humoral thyroid autoimmunity.
DESIGN: Retrospective chart review study of patients treated and monitored with a standard prospective protocol.
SETTING: University hospital in Pisa, Italy, between 1976 and 1994. PATIENTS: 182 patients with differentiated thyroid carcinoma and serum antibodies to thyroid peroxidase, thyroglobulin, or TSH receptor due to coexistent clinical Hashimoto thyroiditis, Graves disease, or focal autoimmune thyroiditis. INTERVENTION: Total thyroidectomy and radioiodine treatment to ablate residual or metastatic thyroid tissue. Regular follow-up with iodine-131 whole-body scanning and serum thyroglobulin measurement. Mean follow-up (+/-SD) was 10.1 +/- 4.1 years (range, 4 to 20 years). MEASUREMENTS: Serum antibodies to thyroid peroxidase, thyroglobulin, and TSH receptor.
RESULTS: Thyroid peroxidase, thyroglobulin, and TSH-receptor antibodies progressively disappeared after the initial treatment. The median disappearance time was 6.3 years for thyroid peroxidase antibodies and 3.0 years for thyroglobulin antibodies. There was a statistically significant correlation between the disappearance of thyroid tissue and that of thyroid antibodies. The coexistence of Hashimoto thyroiditis or Graves disease with thyroid cancer did not modify the pattern of disappearance of thyroid antibody compared with patients with focal autoimmune thyroiditis.
CONCLUSIONS: Complete ablation of thyroid tissue with its antigenic components results in the disappearance of antibodies to all major thyroid antigens, thus supporting the concept that continued antibody production depends on the persistence of autoantigen in the body.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12965943     DOI: 10.7326/0003-4819-139-5_part_1-200309020-00010

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  52 in total

1.  Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.

Authors:  R Michael Tuttle; Hernan Tala; Jatin Shah; Rebecca Leboeuf; Ronald Ghossein; Mithat Gonen; Matvey Brokhin; Gal Omry; James A Fagin; Ashok Shaha
Journal:  Thyroid       Date:  2010-10-29       Impact factor: 6.568

2.  Spontaneous improvement of untreated mild Graves' ophthalmopathy: Rundle's curve revisited.

Authors:  Francesca Menconi; Maria Antonietta Profilo; Marenza Leo; Eleonora Sisti; Maria Antonietta Altea; Roberto Rocchi; Francesco Latrofa; Marco Nardi; Paolo Vitti; Claudio Marcocci; Michele Marinò
Journal:  Thyroid       Date:  2013-12-09       Impact factor: 6.568

Review 3.  Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Gary L Francis; Steven G Waguespack; Andrew J Bauer; Peter Angelos; Salvatore Benvenga; Janete M Cerutti; Catherine A Dinauer; Jill Hamilton; Ian D Hay; Markus Luster; Marguerite T Parisi; Marianna Rachmiel; Geoffrey B Thompson; Shunichi Yamashita
Journal:  Thyroid       Date:  2015-07       Impact factor: 6.568

4.  Thyroglobulin antibody resolution after total thyroidectomy for cancer.

Authors:  Jimmy Xu; Ryan Bergren; David Schneider; Herbert Chen; Rebecca S Sippel
Journal:  J Surg Res       Date:  2015-04-02       Impact factor: 2.192

Review 5.  Graves' hyperthyroidism of recent onset and Graves' orbitopathy: to ablate or not to ablate the thyroid?

Authors:  L Bartalena; C Marcocci; A Lai; M L Tanda
Journal:  J Endocrinol Invest       Date:  2008-06       Impact factor: 4.256

6.  Current concepts and future directions in differentiated thyroid cancer.

Authors:  Donald S A McLeod
Journal:  Clin Biochem Rev       Date:  2010-02

7.  Total thyroidectomy in Basedow-Graves' disease treatment: our experience.

Authors:  M Barbuscia; A Querci; A Tonante; D Paparo; F Taranto; A Ilacqua; E Gagliano; A Milone
Journal:  G Chir       Date:  2015 May-Jun

8.  Prescience of a surgeon in 1980.

Authors:  Sandra M McLachlan
Journal:  Thyroid       Date:  2013-06       Impact factor: 6.568

9.  Anti-thyroglobulin antibodies do not significantly increase the risk of finding iodine avid metastases on post-radioactive iodine ablation scan in low-risk thyroid cancer patients.

Authors:  F Nabhan; K Porter; L Senter; M D Ringel
Journal:  J Endocrinol Invest       Date:  2017-05-16       Impact factor: 4.256

Review 10.  Clinical review: improving the measurement of serum thyroglobulin with mass spectrometry.

Authors:  Andrew N Hoofnagle; Mara Y Roth
Journal:  J Clin Endocrinol Metab       Date:  2013-02-28       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.